Correction to “Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD‐1/PD‐L1 Blockade in Patients With Non‐Small Cell Lung Cancer”
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsCancer, Stress, Anesthesia, and Immune Response · Tryptophan and brain disorders · Pharmacological Receptor Mechanisms and Effects
K. Takagaki, Y. Ohno, T. Otsuki, A. Kubota, T. Kijima, T. Tanaka, “Impact of Exposure to Benzodiazepines on Adverse Effects and Efficacy of PD‐1/PD‐L1 Blockade in Patients With Non‐Small Cell Lung Cancer,” Thoracic Cancer 16, (2025): e70081. https://doi.org/10.1111/1759‐7714.70081.
On the 3.4 Subgroup Analysis Based on irAE Status heading, second paragraph, the below final sentence is incorrect.
In the group of patients without irAEs, ECOG PS ≥ 2 and NLR ≥ 5 were associated with shorter PFS, and high PD‐L1 expression (≥ 50%) was associated with longer PFS (HR 1.08, 95% CI: 0.63–1.83, p = 0.79) and OS (HR 0.67, 95% CI: 0.37–1.21, p = 0.19).
It should be corrected to as follows.
In the group of patients without irAEs, ECOG PS ≥ 2 and NLR ≥ 5 were associated with shorter PFS, and high PD‐L1 expression (≥ 50%) was associated with longer PFS (HR 0.19, 95% CI: 0.09–0.39, p < 0.001) and OS (HR 0.41, 95% CI: 0.20–0.87, p = 0.021).
In Table 7, the value for sex: female in the After PSM: BZRA (+) column was incorrect. Below is the correct Table 7.
We apologize for these errors.